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This is a phase II institutional exploratory trial of biweekly irinotecan and cetuximab administration regimen in metastatic colorectal
cancer patients progressing to at least one previous chemotherapy line. A total of 40 patients were treated between November 2005
and November 2007 with irinotecan 180mgm
 2 and cetuximab 500mgm
 2 q2w (every 2 weeks), in every 21-day cycles, until
unacceptable toxicity or progressive disease. An overall response rate of 22.5% was obtained (two complete and seven partial
responses). The disease control rate was 60%. The time to progression was 3.4 months and the overall survival was 8 months. The
toxicity compared very favourably to weekly cetuximab combination schedules. Grade 3/4 adverse effects were observed in
12 patients. Overall, our results turn up very similar both in terms of toxicity and efficacy to those obtained by weekly and biweekly
administration regimens.
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Cetuximab is an epidermal growth factor receptor (EGFR)-directed
IgG1 chimeric monoclonal antibody showing antitumour activity
in the treatment of advanced colorectal cancer. Cetuximab binds
to the extracellular domain of EGFR when it is in the inactive
configuration, competes for receptor binding by occluding the
ligand-binding region, and thereby blocks ligand-induced EGFR
tyrosine kinase activation (Ciardello and Tortora, 2008)
In a randomised phase II trial comparing a combination of
weekly cetuximab and biweekly irinotecan with weekly cetuximab
monotherapy, this monoclonal antibody proved to have consistent
antitumour activity in patients with advanced colorectal cancer
refractory to irinotecan (Cunningham et al, 2004). This study led
to the approval of cetuximab by the regulatory authorities for the
treatment of irinotecan refractory metastatic colorectal cancer.
Other trials have shown that cetuximab improves survival over
best supportive care alone (Jonker et al, 2007) and might offer
some advantage in patients receiving first or second line therapy
(Van Cutsem et al, 2007, Pessino et al, 2008, Sobrero et al, 2008).
Moreover, it has also proved to be active in combination with
oxaliplatin-based regimens, both in the first (Tabernero et al,
2007) and successive lines of treatment (Souglakos et al, 2007)
In all those studies, cetuximab was administered weekly with
an initial intravenous infusion of 400mgm
 2 on day 1 with
subsequent weekly doses of 250mgm
 2. Although this regimen is
undoubtedly active, the weekly administration of cetuximab is out
of step with administration of the chemotherapy regimens with
which cetuximab is commonly combined. Irinotecan is often
administered at a dose of 180mgm
 2 every 2 weeks. Similarly,
in the first-line setting, combinations of infusional 5-fluorouracil
(5-FU)/folinic acid plus irinotecan (FOLFIRI) or oxaliplatin are
frequently administered on an every 2 weeks basis. The option to
synchronise the administration of cetuximab and concomitant
chemotherapy would reduce the impact of treatment adminis-
tration on patients’ lives and simplify treatment administration
for health-care workers. It is also reasonable to assume that
a simplified schedule may reduce the costs associated with
cetuximab administration.
In a preliminary reported phase I trial, it was shown that
cetuximab can be safely administered at 500mgm
 2 every 2 weeks,
with similar pharmacokinetic and pharmacodynamic behaviour
compared with the weekly schedule (Tabernero et al, 2006). The
biweekly dosing may facilitate the administration of this drug, by
making this therapy more convenient for patients (Tabernero et al,
2008). This publication reports on a phase II trial designed to
explore the antitumour activity of combined irinotecan and
cetuximab, both administered in a biweekly fashion.
MATERIALS AND METHODS
Study design
This was an institutional prospective, single-arm phase II trial
exploring the antitumour activity of biweekly administration of
cetuximab and irinotecan in patients with metastatic colorectal
cancer who had progressed to at least one previous line of
chemotherapy for advanced disease. The primary end point was
response rate. Secondary end points were toxicity, time to
progression, duration of response and overall survival. Patients
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Analysis of data took place on January 2008. All patients gave their
informed consent before treatment and the trial was performed
according to the Institutional Review Board.
Selection of patients
Eligibility criteria were histologically confirmed colorectal adeno-
carcinoma, with progressive metastatic disease to at least one
previous line of chemotherapy. Patients had to be at least 18 years
or older, have a performance status of 0–2, adequate bone marrow
reserve (Hb X8.0gdl
 1, neutrophil count X1.5 10
9/l, platelet
count X100 10
9/l), hepatic and renal function (total bilirubin
o1.5UNL, ASAT and ALAT o2.0UNL and serum creatinine
o2mgdl
 1). Epidermal growth factor receptor immunohisto-
chemistry and k-ras status were not required in the eligibility
criteria.
Therapy
Eligible patients were treated with cetuximab 500mgm
 2 intrave-
nous infusion on day 1 (during 2h on the first infusion and during
1h on subsequent cycles if no adverse reaction had occurred on
the previous administration), followed by irinotecan 180mgm
 2
intravenous infusion on day 1 (during 30min in all cycles). Before
cetuximab, all patients received dexchlorphenamine maleate at a
dose of 5mg intravenously. Antiemetic prophylaxis with dexa-
methasone and ondansetron was given before irinotecan. Patients
were evaluated with blood count, complete serum biochemistry
and CEA before day 1 initially. If no relevant toxicity occurred, this
was then done every other cycle. Treatment was continued until
documented disease progression or unacceptable toxicity, which-
ever occurred first.
Evaluation of safety and response
Evaluation of disease was carried out according to RECIST criteria
(Therasse et al, 2000) every 3–5 cycles. Toxicity was evaluated
according to NCI-CTCAE (version 3.0), before every treatment of
the first three cycles, and every other cycle thereafter if no relevant
toxicity had appeared. Irinotecan dosage was reduced by 25% if
Xgrade 3 diarrhoea was observed. Cetuximab administration was
delayed if cutaneous toxicity Xgrade 3 was observed and restarted
when it had reduced to grade 2.
Statistical analysis
Times to event variables were calculated according to Kaplan–
Meier methods using StatSoft (version 6). Descriptive variables of
patient characteristics and toxicity were calculated directly from the
database. Time to tumour progression (TTP) was defined as the
time to documented progression from the start of the treatment,
duration of response (DR) as the time from first objective response
to documented progression and overall survival (OS) was consi-
dered from the start of treatment to date of data analysis or date of
loss from follow-up for patients alive. Patients without disease
progression who discontinued the study for any reason were
censored at the last on study tumour assessment date. All efficacy
and safety analyses were evaluated at an exploratory level.
RESULTS
Between November 2005 and November 2007, a total of 40 patients
were recruited. Patient characteristics are shown in Table 1.
Median age at diagnosis was 61 years. The median performance
status at the start of treatment was 1. Patients had received a
median of one previous chemotherapy line for advanced disease,
but 27.5% had two previous lines and 20% got this therapy as
fourth or further line. The median number of metastatic sites
was 2. Almost all patients were pretreated with oxaliplatin- and
fluoropyrimidine-based combinations. Half of them received
previous treatment with bevacizumab and 25% received irinotecan-
based therapies. The median follow-up time for the patients alive
was 5 months (range: 4–24.5). A total of 322 treatment cycles were
administered, which amounts to a median of 7 cycles per patient
(range: 2–29).
Efficacy
A total of 39 patients were assessed for response. There was an
overall response rate of 22.5% (two complete and seven partial
Table 1 Baseline characteristics of patients
Characteristic
Age – median (range) (years) 62 (33–78)
Sex – n (%)
Male 19 (47)
Female 21 (53)
Performance status – n (%)
0 9 (22.5)
1 25 (62.5)
2 6 (15)
No. of metastatic localizations at start of treatment – n (%)
1 8 (20)
2 16 (40)
3 12 (30)
4 2 (5)
5 2 (5)
No. of previous treatments for mCRC – n (%)
1 21 (52.5)
2 11 (27.5)
3 or more 8 (20)
Prior therapy for mCRC – n (%)
Oxaliplatin 39 (97.5)
Fluoropyrimidine 40 (100)
Irinotecan 10 (25)
Bevacizumab 20 (50)
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Median time to progression: 3.4 months
Figure 1 Progression-free survival Kaplan–Meier curve. The median
time to progression was 3.4 months (range: 0.7–23.9). Thirty-six out of 40
patients had progressed at the time of analysis.
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sresponses, CI 95%: 9.6–35.4%). Stable disease was observed in
15 cases (37.5%). The disease control rate was 60% (CI 95%:
44.9–75.1%). Progressive disease was observed in 15 patients. One
patient was not assessable because she died before evaluation. The
median TTP was 3.4 months (range: 0.7–23.9). Figure 1 shows
the progression-free survival curve. The median OS from the start
of treatment was 8 months (range: 0.7–26.1). Figure 2 shows the
Kaplan–Meier OS curve. Eight out of the nine responding patients
had progressed at the time of analysis. The median duration of
response was 5.0 months (range: 2–20).
Safety
The biweekly administration of cetuximab and irinotecan proved
to be tolerable. Considering maximum reported toxicity by patient,
the only grade 4 observed event was diarrhoea in two patients
(5%). Two more patients suffered from grade 3 diarrhoea (5%).
Grade 3 skin rash was seen in three patients (7.5%). Grade 3
anaemia and neutropoenia were reported in one (2.5%) and three
(7.5%) cases, respectively. Only one case of grade 3 nausea was
seen. Neither grade 4 myelosuppression nor severe infusional
anaphylactic reactions were observed. Concerning grade 2 events,
paronychia was reported in 30% of patients, alopecia in 7.5%, skin
rash in 17.5% and asthenia in 15%. No treatment related deaths
occurred.
DISCUSSION
The aim of this exploratory trial was to investigate the antitumour
activity of the combination of irinotecan and cetuximab given in a
biweekly fashion, as well as its safety profile with respect to the
standard weekly regimen used in most trials with cetuximab. The
efficacy data obtained in the different studies of irinotecan and
cetuximab given weekly or biweekly are listed in Table 2. The
response rate seen in this trial is very similar to that observed with
weekly cetuximab administration in the BOND trial (Cunningham
et al, 2004). Also time to progression (3.4 vs 4.1 months) and
overall survival (8 vs 8.6 months) illustrate the similarities of both
schedules. Our results are also comparable to those obtained in a
large confirmatory trial accruing more than 1000 patients (Wilke
et al, 2006). Safety between the different schedules is compared in
Table 3. In terms of toxicity, the biweekly regimen also proved to
be tolerable. Grade 3 or 4 events were mainly observed only in
eight (20) and two (5%) of our patients, respectively. Pfeiffer et al
reported very similar results using a biweekly cetuximab and
irinotecan regimen. Their results using the biweekly schedule were
comparable to those of a 65 patients historical cohort receiving the
weekly schedule at the same participating institutions.
Different phase I and II trials have studied the pharmacokinetic
and pharmacodynamic behaviour of cetuximab in different dosing
schedules. Fairly predictable linear pharmacokinetic has been
demonstrated for cetuximab. Multiple dose studies have demon-
strated that the pharmacokinetic parameters – CL, AUC, t1/2 and
volume of distribution at steady state (Vss) – are similar after single
and multiple doses of cetuximab at the approved dosing regimen.
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Median survival: 8 months
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Figure 2 Overall survival Kaplan–Meier curve. The median overall
survival time from the start of treatment was 8 months (range: 0.7–26.1).
Twenty-eight patients out of the 40 registered in the trial had died at the
time of analysis.
Table 3 Grade 3 or 4 adverse events reported in the treatment of metastatic colorectal cancer patients with irinotecan and cetuximab combination:
comparison between the weekly and biweekly administration schedules
Weekly regimens (%) Biweekly regimens (%)
Adverse event
Cunningham et al
(2004) (N¼327)
Wilke et al (2006)
(N¼1147)
Pfeiffer et al
(2008) (N¼65)
Pfeiffer et al
(2008) (N¼74)
This study
(N¼40)
Diarrhoea 21 20 10 9 10
Skin or nail toxicity 9 19 11 8 7.5
Fatigue/asthenia 14 8 8 4 0
Neutropoenia 9 10 4 7 7.5
Table 2 Efficacy of cetuximab and irinotecan in metastatic colorectal cancer patients refractory to irinotecan-based therapy: comparison between weekly
and biweekly combination regimens
Weekly regimens Biweekly regimens
Cunningham et al
(2004) (N¼329)
Wilke et al (2006)
(N¼1147)
Pfeiffer et al
(2008) (N¼65)
Pfeiffer et al
(2008) (N¼74)
This study
(N¼40)
RR (%) 22.9 20 20 25.7 22.5
TTP (months) 4.1 NR 5.4 4.8 3.4
OS (months) 8.6 9.2 10.4 9.8 8
NR¼not reported; OS¼overall survival; TTP¼time to progression.
Biweekly cetuximab and irinotecan in colon cancer
P Martı ´n-Martorell et al
457
British Journal of Cancer (2008) 99(3), 455–458 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sThe AUC also shows a linear relationship to the dose and
frequency of administration (Humblet et al, 2005). The data
regarding pharmcokinetic and pharmacodynamic behaviour of
cetuximab at different dosages and frequency schedules support
the feasibility of biweekly cetuximab administration in combina-
tion with irinotecan (Tabernero et al, 2006).
Furthermore, the different trials using the simplified biweekly
administration have all yielded very consistent results, both with
regard to the TTP and OS, as well as to the response rate. Both our
results and those recently published by Pfeiffer et al, show very
similar efficacy data compared to the weekly schedule. Adminis-
tering irinotecan and cetuximab together every 2 weeks would
render conveniency both for patients and for the health resources,
without compromising efficacy or having a deleterious effect on
toxicity. It therefore appears as a very reasonable strategy that
would be worth testing in future trials.
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